Literature DB >> 8161790

Mutations of the N-ras gene in juvenile chronic myelogenous leukemia.

J Miyauchi1, M Asada, M Sasaki, Y Tsunematsu, S Kojima, S Mizutani.   

Abstract

Juvenile chronic myelogenous leukemia (JCML), a myeloproliferative disorder of childhood, is distinct from adult-type chronic myelogenous leukemia (CML) and bears resemblance to chronic myelomonocytic leukemia (CMMoL). Since mutations in the N-ras gene have been found at high frequencies in CMMoL, but only rarely in CML, we analyzed mutations activating the N-ras gene in 20 patients with JCML. We used the strategy for analysis of gene mutations based on in vitro DNA amplification by polymerase chain reaction (PCR) followed by single-strand conformation polymorphism (SSCP) analysis and/or direct sequence analysis. Nucleotide sequence analysis showed single nucleotide substitutions involving codons 12, 13, or 61 in six of 20 patients (30%). Four of six patients with mutations were in chronic phase and the other two in blast crisis, indicating no apparent correlation with disease stage. Most of the patients with mutations were in the older age group with poor prognosis, although one patient in the younger age group also harbored the mutation. These data suggest that N-ras gene mutations may be involved in the pathogenesis and/or prognosis of JCML and provide further evidence that JCML is an entity distinct from CML.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8161790

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  25 in total

1.  Inhibiting the palmitoylation/depalmitoylation cycle selectively reduces the growth of hematopoietic cells expressing oncogenic Nras.

Authors:  Jin Xu; Christian Hedberg; Frank J Dekker; Qing Li; Kevin M Haigis; Eugene Hwang; Herbert Waldmann; Kevin Shannon
Journal:  Blood       Date:  2011-12-05       Impact factor: 22.113

Review 2.  RAS inhibitors in hematologic cancers: biologic considerations and clinical applications.

Authors:  D M Beaupre; R Kurzrock
Journal:  Invest New Drugs       Date:  1999       Impact factor: 3.850

Review 3.  Chronic myelomonocytic leukemia and atypical chronic myeloid leukemia: novel pathogenetic lesions.

Authors:  Hideki Muramatsu; Hideki Makishima; Jaroslaw P Maciejewski
Journal:  Semin Oncol       Date:  2012-02       Impact factor: 4.929

4.  Genetic disruption of the PI3K regulatory subunits, p85α, p55α, and p50α, normalizes mutant PTPN11-induced hypersensitivity to GM-CSF.

Authors:  Charles B Goodwin; Zhenyun Yang; Fuqin Yin; Menggang Yu; Rebecca J Chan
Journal:  Haematologica       Date:  2012-02-07       Impact factor: 9.941

5.  Establishment of a monosomy 7 leukemia cell line, MONO-7, with a ras gene mutation.

Authors:  Hiroyuki Fujisaki; Kenji Takai; Sawada Akihisa; Sadao Tokimasa; Yoshiko Matsuda; Hideaki Ohta; Yuko Osugi; Ji Yoo Kim; Gaku Hosoi; Masahiro Sako; Junichi Hara
Journal:  Int J Hematol       Date:  2002-01       Impact factor: 2.490

6.  Ral is both necessary and sufficient for the inhibition of myeloid differentiation mediated by Ras.

Authors:  Nader Omidvar; Lorna Pearn; Alan K Burnett; Richard L Darley
Journal:  Mol Cell Biol       Date:  2006-05       Impact factor: 4.272

7.  PTPN11 is the first identified proto-oncogene that encodes a tyrosine phosphatase.

Authors:  Rebecca J Chan; Gen-Sheng Feng
Journal:  Blood       Date:  2006-10-19       Impact factor: 22.113

8.  Functional analysis of leukemia-associated PTPN11 mutations in primary hematopoietic cells.

Authors:  Suzanne Schubbert; Kenneth Lieuw; Sara L Rowe; Connie M Lee; Xiaxin Li; Mignon L Loh; D Wade Clapp; Kevin M Shannon
Journal:  Blood       Date:  2005-03-10       Impact factor: 22.113

Review 9.  Role of Ras/Raf/MEK/ERK signaling in physiological hematopoiesis and leukemia development.

Authors:  Eva Chung; Motonari Kondo
Journal:  Immunol Res       Date:  2011-04       Impact factor: 2.829

10.  Determination of Ras-GTP and Ras-GDP in patients with acute myelogenous leukemia (AML), myeloproliferative syndrome (MPS), juvenile myelomonocytic leukemia (JMML), acute lymphocytic leukemia (ALL), and malignant lymphoma: assessment of mutational and indirect activation.

Authors:  D Raepple; F von Lintig; T Zemojtel; M Duchniewicz; A Jung; M Lübbert; G R Boss; J S Scheele
Journal:  Ann Hematol       Date:  2008-09-11       Impact factor: 3.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.